Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH
Garrido P (1), Aldaz A (2), Vera R (3), Calleja MA (4), de Álava E (5,6), Martín M (6,7), Matías-Guiu X (6,8), Palacios J (9,10).
(1) Medical Oncology, Ramón y Cajal University Hospital, IRYCIS, University of Alcalá, Madrid, Spain.
(2) Pharmacy, Clínica Universidad de Navarra, Working Group PkGen from the SEFH, Pamplona, Spain.
(3) Medical Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain.
(4) Pharmacy, Virgen de Macarena University Hospital, Seville, Spain.
(5) Pathology, Virgen del Rocío University Hospital, Institute of Biomedicine of Seville (IBiS)/CSIC/University of Sevilla, Seville, Spain.
(6) Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain.
(7) Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain.
(8) Pathology and Molecular Genetics, Hospital Universitari de Bellvitge, IDIBELL Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLLEIDA, Lleida, Spain.
(9) Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain.
(10) Pathology, Ramón y Cajal University Hospital, IRYCIS, University of Alcalá, Madrid, Spain.
Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.
Precision medicine is transforming clinical and biomedical research, as well as health care itself from a conceptual, as well as a methodological viewpoint, providing extraordinary opportunities to improve public health and lower the costs of the healthcare system.
However, the implementation of precision medicine poses ethical-legal, regulatory, organizational, and knowledge-related challenges. Without a national strategy, precision medicine, which will be implemented one way or another, could take place without the appropriate planning that can guarantee technical quality, equal access of all citizens to the best practices, violating the rights of patients and professionals, and jeopardizing the solvency of the healthcare system.
With this paper from the Spanish Societies of Medical Oncology, Pathology, and Hospital Pharmacy, we highlight the need to institute a consensual national strategy for the development of precision medicine in our country, review the national and international context, comment on the opportunities and challenges for implementing precision medicine, and outline the objectives of a national strategy on precision medicine in cancer.
CITA DEL ARTÍCULO Clin Transl Oncol. 2017 Aug 31. doi: 10.1007/s12094-017-1740-0